SCHEMBL1016524

SCHEMBL1016524

COC(=O)c1cc(Cl)ccc1NC(=O)COCC(=O)Nc1cccc(-c2cc3ccccc3o2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.46
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.44
MAPT P10636 3/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 2/20 0.42
G6PD P11413 1/20 0.42
P2RY14 Q15391 2/20 0.42
MAOB P27338 1/20 0.42
SERPINE1 P05121 1/20 0.42
HSD17B10 Q99714 3/20 0.41
GAA P10253 2/20 0.41
USP2 O75604 2/20 0.41
TSHR P16473 2/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015654 0.91 POLB (0.52) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL1016295 0.84 LCLAT1 (0.49) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL1013377 0.82 SERPINE1 (0.43) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL1015897 0.81 EDNRA (0.49) NPC1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL1015662 0.80 SERPINE1 (0.64) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL1015837 0.80 CNR1 (0.51) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL1015635 0.80 CNR1 (0.51) SMN1; SMN2MEN1KMT2AMAPTKDM4E
SCHEMBL1016790 0.79 SERPINE1 (0.47) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL1015061 0.79 CNR1 (0.53) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL1016282 0.79 SERPINE1 (0.47) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 NPC1 1613/4885RAB9A 2950/4885SMN1; SMN2 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.